{"id":68229,"date":"2026-06-15T21:53:11","date_gmt":"2026-06-15T13:53:11","guid":{"rendered":"https:\/\/flcube.com\/?p=68229"},"modified":"2026-06-15T21:53:13","modified_gmt":"2026-06-15T13:53:13","slug":"sichuan-biokins-iza-bren-becomes-worlds-first-egfrxher3-bispecific-adc-with-nda-accepted-by-chinas-nmpa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68229","title":{"rendered":"Sichuan Biokin&#8217;s Iza-Bren Becomes World&#8217;s First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China&#8217;s NMPA"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Biokin Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>)<\/strong> announced that the <strong>new drug application (NDA)<\/strong> for its independently developed <strong>Izalontamab brengitecan (iza-bren)<\/strong> has been <strong>formally accepted for review<\/strong> by China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>. This milestone establishes iza-bren as the <strong>world&#8217;s first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC)<\/strong> to achieve NDA acceptance and the <strong>only EGFR\u00d7HER3 bispecific ADC in Phase III clinical trials globally<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA\/CDE (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Formally accepted for review<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Izalontamab brengitecan (iza-bren)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>First-in-class EGFR\u00d7HER3 bispecific ADC<\/td><\/tr><tr><td><strong>Global Significance<\/strong><\/td><td>World&#8217;s first EGFR\u00d7HER3 bispecific ADC with NDA acceptance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-additional-nda-submissions-under-review\" class=\"wp-block-heading\">Additional NDA Submissions Under Review<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Locally advanced or metastatic nasopharyngeal carcinoma<\/strong><\/li>\n\n\n\n<li><strong>Recurrent or metastatic esophageal squamous cell carcinoma<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-product-profile-amp-innovation\" class=\"wp-block-heading\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> First-in-class dual-targeting approach combining EGFR and HER3 pathways<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Phase III clinical trials (only EGFR\u00d7HER3 bispecific ADC at this stage globally)<\/li>\n\n\n\n<li><strong>Clinical Program:<\/strong> Over 40 clinical trials across China and United States<\/li>\n\n\n\n<li><strong>Therapeutic Scope:<\/strong> Broad range of tumor types under evaluation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-recognition-amp-designations\" class=\"wp-block-heading\">Regulatory Recognition &amp; Designations<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Jurisdiction<\/th><th>Designation Type<\/th><th>Count<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>China (CDE)<\/strong><\/td><td>Breakthrough Therapy<\/td><td>7<\/td><td>Accelerated development pathway<\/td><\/tr><tr><td><strong>China (CDE)<\/strong><\/td><td>Priority Review<\/td><td>2<\/td><td>Expedited regulatory review<\/td><\/tr><tr><td><strong>U.S. (FDA)<\/strong><\/td><td>Breakthrough Therapy<\/td><td>1<\/td><td>FDA expedited development program<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-market-positioning\" class=\"wp-block-heading\">Strategic Market Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Unprecedented position as world&#8217;s first EGFR\u00d7HER3 bispecific ADC with NDA acceptance<\/li>\n\n\n\n<li><strong>Dual Receptor Targeting:<\/strong> Simultaneous inhibition of EGFR and HER3 addresses tumor heterogeneity and resistance mechanisms<\/li>\n\n\n\n<li><strong>ADC Platform Validation:<\/strong> Demonstrates Sichuan Biokin&#8217;s advanced antibody-drug conjugate capabilities<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Parallel clinical programs in China and U.S. support worldwide commercial potential<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-portfolio\" class=\"wp-block-heading\">Clinical Development Portfolio<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The extensive clinical program spanning <strong>over 40 trials<\/strong> reflects the molecule&#8217;s broad therapeutic potential across multiple solid tumor indications. The simultaneous NDA acceptance for multiple tumor types demonstrates strong clinical data supporting efficacy across different cancer contexts.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Competitive Position<\/th><\/tr><\/thead><tbody><tr><td><strong>EGFR\u00d7HER3 Targeting<\/strong><\/td><td>Only bispecific ADC in this class globally<\/td><\/tr><tr><td><strong>Phase III Status<\/strong><\/td><td>Sole EGFR\u00d7HER3 bispecific ADC at late-stage development<\/td><\/tr><tr><td><strong>Regulatory Momentum<\/strong><\/td><td>Unprecedented combination of breakthrough and priority designations<\/td><\/tr><tr><td><strong>Geographic Reach<\/strong><\/td><td>Simultaneous development in China and U.S. markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-assessment\" class=\"wp-block-heading\">Market Opportunity Assessment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EGFR\/HER3-Expressing Tumors:<\/strong> Large addressable patient populations across multiple cancer types<\/li>\n\n\n\n<li><strong>ADC Market Growth:<\/strong> Global ADC market projected to exceed $20 billion by 2030<\/li>\n\n\n\n<li><strong>China Oncology Market:<\/strong> Rapidly expanding market for innovative cancer therapies<\/li>\n\n\n\n<li><strong>Premium Pricing Potential:<\/strong> First-in-class status supports significant pricing power<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps-amp-timeline-expectations\" class=\"wp-block-heading\">Next Steps &amp; Timeline Expectations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Review Period:<\/strong> Standard 200-day review timeline with potential acceleration due to priority designations<\/li>\n\n\n\n<li><strong>Potential Approval:<\/strong> Anticipated 2027 approval pending successful review completion<\/li>\n\n\n\n<li><strong>Commercial Preparation:<\/strong> Manufacturing scale-up and commercial infrastructure development underway<\/li>\n\n\n\n<li><strong>Additional Indications:<\/strong> Continued clinical development across remaining tumor types in pipeline<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-sichuan-biokin\" class=\"wp-block-heading\">Strategic Implications for Sichuan Biokin<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This NDA acceptance represents a transformative milestone for Sichuan Biokin, potentially establishing the company as a global leader in next-generation bispecific ADC technology. The world-first achievement validates the company&#8217;s innovative approach to dual-receptor targeting and positions iza-bren for significant commercial success.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260615_1QN8.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260615_1QN8.\"><\/object><a id=\"wp-block-file--media-f351df18-1f3e-4aec-bcb0-9c96b9dd4a3f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260615_1QN8.pdf\">688506_20260615_1QN8<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260615_1QN8.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f351df18-1f3e-4aec-bcb0-9c96b9dd4a3f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,151,16,38,857],"class_list":["post-68229","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-cancer","tag-market-approval-filings","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin&#039;s Iza-Bren Becomes World&#039;s First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China&#039;s NMPA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for its independently developed Izalontamab brengitecan (iza-bren) has been formally accepted for review by China&#039;s National Medical Products Administration (NMPA). This milestone establishes iza-bren as the world&#039;s first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) to achieve NDA acceptance and the only EGFR\u00d7HER3 bispecific ADC in Phase III clinical trials globally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68229\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin&#039;s Iza-Bren Becomes World&#039;s First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China&#039;s NMPA\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for its independently developed Izalontamab brengitecan (iza-bren) has been formally accepted for review by China&#039;s National Medical Products Administration (NMPA). This milestone establishes iza-bren as the world&#039;s first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) to achieve NDA acceptance and the only EGFR\u00d7HER3 bispecific ADC in Phase III clinical trials globally.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68229\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:53:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:53:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68229#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68229\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin&#8217;s Iza-Bren Becomes World&#8217;s First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China&#8217;s NMPA\",\"datePublished\":\"2026-06-15T13:53:11+00:00\",\"dateModified\":\"2026-06-15T13:53:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68229\"},\"wordCount\":553,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Cancer\",\"Market approval filings\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68229#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68229\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68229\",\"name\":\"Sichuan Biokin's Iza-Bren Becomes World's First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China's NMPA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-15T13:53:11+00:00\",\"dateModified\":\"2026-06-15T13:53:13+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for its independently developed Izalontamab brengitecan (iza-bren) has been formally accepted for review by China's National Medical Products Administration (NMPA). This milestone establishes iza-bren as the world's first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) to achieve NDA acceptance and the only EGFR\u00d7HER3 bispecific ADC in Phase III clinical trials globally.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68229#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68229\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68229#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin&#8217;s Iza-Bren Becomes World&#8217;s First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China&#8217;s NMPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin's Iza-Bren Becomes World's First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for its independently developed Izalontamab brengitecan (iza-bren) has been formally accepted for review by China's National Medical Products Administration (NMPA). This milestone establishes iza-bren as the world's first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) to achieve NDA acceptance and the only EGFR\u00d7HER3 bispecific ADC in Phase III clinical trials globally.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68229","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin's Iza-Bren Becomes World's First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China's NMPA","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for its independently developed Izalontamab brengitecan (iza-bren) has been formally accepted for review by China's National Medical Products Administration (NMPA). This milestone establishes iza-bren as the world's first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) to achieve NDA acceptance and the only EGFR\u00d7HER3 bispecific ADC in Phase III clinical trials globally.","og_url":"https:\/\/flcube.com\/?p=68229","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T13:53:11+00:00","article_modified_time":"2026-06-15T13:53:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68229#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68229"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin&#8217;s Iza-Bren Becomes World&#8217;s First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China&#8217;s NMPA","datePublished":"2026-06-15T13:53:11+00:00","dateModified":"2026-06-15T13:53:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68229"},"wordCount":553,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Cancer","Market approval filings","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68229#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68229","url":"https:\/\/flcube.com\/?p=68229","name":"Sichuan Biokin's Iza-Bren Becomes World's First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China's NMPA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-15T13:53:11+00:00","dateModified":"2026-06-15T13:53:13+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for its independently developed Izalontamab brengitecan (iza-bren) has been formally accepted for review by China's National Medical Products Administration (NMPA). This milestone establishes iza-bren as the world's first EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) to achieve NDA acceptance and the only EGFR\u00d7HER3 bispecific ADC in Phase III clinical trials globally.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68229#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68229"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68229#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin&#8217;s Iza-Bren Becomes World&#8217;s First EGFR\u00d7HER3 Bispecific ADC with NDA Accepted by China&#8217;s NMPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68229"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68229\/revisions"}],"predecessor-version":[{"id":68231,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68229\/revisions\/68231"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}